BioInvent Secures €1 Million Milestone as Endometriosis Antibody Enters Phase 3

BioInvent International AB ( (SE:BINV) ) just unveiled an announcement.

BioInvent International has reached a key development milestone under its license agreement for HMI-115, an anti-prolactin receptor antibody aimed at treating moderate to severe endometriosis-associated pain. The milestone was triggered by partner Hope Medicine’s initiation of a randomized, double-blind, placebo-controlled Phase 3 trial in China, which will enroll about 540 pre-menopausal women across several major cities.

The achievement entitles BioInvent to a €1 million payment and underscores the commercial potential of its antibody discovery platforms as more out-licensed candidates advance in global pipelines. With three partnered antibodies now in clinical development, the company is positioned to capture further value through additional milestones and potential future royalties, reinforcing its strategy of leveraging collaborations to monetize its technology beyond oncology.

The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.

More about BioInvent International AB

BioInvent International AB is a Swedish clinical-stage biotech company focused on discovering and developing first-in-class immuno-modulatory antibodies for cancer therapy. Its proprietary F.I.R.S.T. and n-CoDeR technology platforms generate novel antibody candidates for hematological malignancies and solid tumors, supporting both the company’s own pipeline and multiple partnerships that provide collaboration and manufacturing revenues.

Average Trading Volume: 107,358

Technical Sentiment Signal: Sell

Current Market Cap: SEK1.55B

For an in-depth examination of BINV stock, go to TipRanks’ Overview page.